Bioequivalence is the easy part. Freedom to Operate is the cliff.
In the last few years, the pathway for bringing an abbreviated drug to market has become clearerat least on paper. If you can demonstrate bioequivalence, you can often check the regulato…

The Safe Patent Portfolio Trap: Why Minimal Filing Costs Can Quietly Stall Pharma Growth
In the early days of a new portfolio strategy, low spend on filings feels like financial discipline. Fewer filings. Lower upfront legal costs. Faster decision cycl…

Most people think Paragraph IV is about legal theory. In practice, its about moneyand the hidden clauses that turn a standard filing into a $50 million problem.
Drugmakers love to call it a notice letter costly litigation risk or the price of pursuing …

The At-Risk Launch Playbook Is Backand Its Built on Math, Not Hope
A quiet shift is happening across branded pharma and generics: more companies are choosing to launch at risknot because the legal outcome is certain, but because the expected value math…

Evergreen​ing is the headline everyone understandsbut the mechanics are where the story gets interesting.
For years, evergreening has been used as a catch-all explanation for why drug prices stay high: tweak a formulation, file another patent, block …

Early doesnt mean small. In patent litigation, it often means everything.
Most people think about patent cases as slow, expensive marathonsbriefs, expert reports, long timelines, and maybe a win years later. But theres a different, often underappreci…

The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
If youre betting on FDA Paragraph IV exclusivity as your ticket to profit, read this twice.
For years, the industrys shorthand has been simple: file first, earn 180 days of mark…

Most pharma teams treat settlement like a finish line. Thats the expensive mistake.
In the patent world, settlement is often framed as de-risking. But too many companies use it as a default strategybefore the economics, the evidence, and the timelines …

Device patents dont always get the credit they deserve in pharma strategy. But if you zoom out, they often act like the thin, decisive weakest wall in a drugs intellectual property fortress.
Heres the reality: when a challenge comes, its rarely an abst…

A new patent shouldnt feel like a shell game. But the salt change trap often does.
For patients, clinicians, and investors, drug approvals can look clean on the surface: a molecule gets sanctioned, manufacturing ramps, competition begins. Yet hidden in…